Published in Ann Surg Oncol on June 18, 2010
Trends in radical prostatectomy: centralization, robotics, and access to urologic cancer care. Cancer (2011) 3.13
Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women. BMJ (2012) 2.88
Association of distance from a transplant center with access to waitlist placement, receipt of liver transplantation, and survival among US veterans. JAMA (2014) 1.95
Fragmentation in specialist care and stage III colon cancer. Cancer (2015) 1.41
National trends in resection of the distal pancreas. World J Gastroenterol (2012) 1.07
Diverging trends in recent population-based survival rates in oesophageal and gastric cancer. PLoS One (2012) 0.89
Racial disparities in changing to a high-volume urologist among men with localized prostate cancer. Med Care (2011) 0.88
Collaboration Between Surgeons and Medical Oncologists and Outcomes for Patients With Stage III Colon Cancer. J Oncol Pract (2015) 0.84
Factors associated with use of preoperative chemoradiation therapy for rectal cancer in the Cancer Care Outcomes Research and Surveillance Consortium. Am J Clin Oncol (2013) 0.83
Minimum volume standards in German hospitals: do they get along with procedure centralization? A retrospective longitudinal data analysis. BMC Health Serv Res (2015) 0.81
Surgical quality is more than volume: the association between changing urologists and complications for patients with localized prostate cancer. Health Serv Res (2014) 0.79
Association between surgeon characteristics and their preferences for guideline-concordant staging and treatment for rectal cancer. Am J Surg (2014) 0.79
Re-organisation of oesophago-gastric cancer services in England and Wales: a follow-up assessment of progress and remaining challenges. BMC Res Notes (2014) 0.77
Disclosure of surgeon experience. World J Surg (2014) 0.76
Reorganising specialist cancer surgery for the twenty-first century: a mixed methods evaluation (RESPECT-21). Implement Sci (2016) 0.75
Complex and Reoperative Colorectal Surgery: Setting Expectations and Learning from Experience. Clin Colon Rectal Surg (2016) 0.75
Readmissions After Colon Cancer Surgery: Does It Matter Where Patients Are Readmitted? J Oncol Pract (2016) 0.75
Multimorbidity and access to major cancer surgery at high-volume hospitals in a regionalized era. Am J Surg (2016) 0.75
Nationwide outcomes of nontrauma splenectomy. Surg Endosc (2014) 0.75
Is There a Rationale for Structural Quality Assurance in Esophageal Surgery? Visc Med (2017) 0.75
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol (2007) 11.77
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol (2004) 9.73
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol (2003) 8.95
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol (2008) 8.72
American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites. J Clin Oncol (2008) 4.79
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Global gene expression profiling of circulating tumor cells. Cancer Res (2005) 3.41
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol (2007) 3.37
Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol (2008) 3.34
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol (2014) 3.20
Patients' decision-making process regarding participation in phase I oncology research. J Clin Oncol (2006) 2.72
Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol (2002) 2.41
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol (2010) 2.41
Centralization of cancer surgery: implications for patient access to optimal care. J Clin Oncol (2009) 2.40
Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer (2008) 1.89
The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist (2007) 1.89
The culture of faith and hope: patients' justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials. Cancer (2010) 1.84
Correlates of colorectal cancer screening compliance and stage of adoption among siblings of individuals with early onset colorectal cancer. Health Psychol (2002) 1.84
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol (2008) 1.80
Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer (2006) 1.72
Facilitating informed decisions regarding microsatellite instability testing among high-risk individuals diagnosed with colorectal cancer. J Clin Oncol (2010) 1.69
The correlation between patient characteristics and expectations of benefit from Phase I clinical trials. Cancer (2003) 1.65
Predictors of long-term outcomes in older breast cancer survivors: perceptions versus patterns of care. J Clin Oncol (2003) 1.54
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer (2007) 1.52
Communication between physicians and older women with localized breast cancer: implications for treatment and patient satisfaction. J Clin Oncol (2002) 1.49
The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations. J Oncol Pract (2013) 1.48
Telomerase is frequently activated in tumors with microsatellite instability. Cancer Biol Ther (2004) 1.47
The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity. Proc Natl Acad Sci U S A (2003) 1.41
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res (2005) 1.39
Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas (2008) 1.38
Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer (2005) 1.37
Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. Cancer Biol Ther (2007) 1.35
Expectations of benefit in early-phase clinical trials: implications for assessing the adequacy of informed consent. Med Decis Making (2008) 1.34
Proteomic analyses of pancreatic cyst fluids. Pancreas (2009) 1.29
A randomized trial of generic versus tailored interventions to increase colorectal cancer screening among intermediate risk siblings. Ann Behav Med (2009) 1.26
Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. Clin Cancer Res (2012) 1.21
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol (2003) 1.17
Multiple behavioral risk factors for colorectal cancer and colorectal cancer screening status. Cancer Epidemiol Biomarkers Prev (2007) 1.16
The American Society of Clinical Oncology's Blueprint for Transforming Clinical and Translational Cancer Research. J Clin Oncol (2012) 1.16
Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys (2011) 1.13
Understanding how out-of-pocket expenses, treatment value, and patient characteristics influence treatment choices. Oncologist (2010) 1.12
Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question? J Clin Oncol (2012) 1.11
Understanding intention to undergo colonoscopy among intermediate-risk siblings of colorectal cancer patients: a test of a mediational model. Prev Med (2003) 1.10
Patient and provider characteristics that affect the use of axillary dissection in older women with stage I-II breast carcinoma. Cancer (2002) 1.08
Cost concerns of patients with cancer. J Oncol Pract (2013) 1.07
Using health communication best practices to develop a web-based provider-patient communication aid: the CONNECT study. Patient Educ Couns (2008) 1.05
Ongoing challenge of stage II colon cancer. J Clin Oncol (2011) 1.04
Targeting signal transduction pathways in colorectal cancer--more than skin deep. J Clin Oncol (2005) 1.04
Circulating tumor cells: evolving evidence and future challenges. Oncologist (2009) 1.04
Cancer patients' trade-offs among efficacy, toxicity, and out-of-pocket cost in the curative and noncurative setting. Med Care (2013) 1.04
Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys (2007) 1.03
2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2002) 1.03
Loss of methylthioadenosine phosphorylase and elevated ornithine decarboxylase is common in pancreatic cancer. Clin Cancer Res (2004) 1.02
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res (2002) 1.02
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome. Int J Gastrointest Cancer (2003) 1.01
Knowledge and attitudes about microsatellite instability testing among high-risk individuals diagnosed with colorectal cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.00
Gastric Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw (2006) 1.00
Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma. Int J Radiat Oncol Biol Phys (2007) 1.00
Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas. Oncologist (2013) 0.98
Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. Cancer (2004) 0.97
Cancer genetic risk assessment and referral patterns in primary care. Genet Test Mol Biomarkers (2009) 0.96
Cost implications of new treatments for advanced colorectal cancer. Cancer (2009) 0.96
KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice. Oncologist (2011) 0.96
End points in advanced colon cancer clinical trials: a review and proposal. J Clin Oncol (2007) 0.95
Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation. Int J Radiat Oncol Biol Phys (2008) 0.95
Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer. Clin Cancer Res (2002) 0.94
Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma. Am J Clin Oncol (2011) 0.94
Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol (2009) 0.93
Esophageal cancer. J Natl Compr Canc Netw (2008) 0.93
Comparative effectiveness research to inform medical decisions: the need for common language. J Clin Oncol (2012) 0.92
Esophageal cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2003) 0.92
Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase. Cancer Res (2010) 0.92
Preoperative chemoradiation in the management of adenocarcinoma of the body of the pancreas. Am Surg (2002) 0.90
An exploration of relative health stock in advanced cancer patients. Med Decis Making (2004) 0.90
Talking with patients about dying. N Engl J Med (2013) 0.90
An Internet method to assess cancer patient information needs and enhance doctor-patient communication: a pilot study. J Cancer Educ (2007) 0.89
Understanding of an aggregate probability statement by patients who are offered participation in Phase I clinical trials. Cancer (2005) 0.89
A new era for the systemic therapy of neuroendocrine tumors. Oncologist (2012) 0.89
Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer. Radiother Oncol (2012) 0.88
Value and cancer care: toward an equitable future. Clin Cancer Res (2010) 0.88
Influence of delays to nonemergent colon cancer surgery on operative mortality, disease-specific survival and overall survival. Can J Surg (2009) 0.88
A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study. J Gastrointest Cancer (2012) 0.88
Esophageal Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw (2006) 0.87
Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report. Ann Surg Oncol (2006) 0.87
A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs. Value Health (2012) 0.87
Assessing compliance with national comprehensive cancer network guidelines for elderly patients with stage III colon cancer: the Fox Chase Cancer Center Partners' initiative. Clin Colorectal Cancer (2011) 0.86
Gastric cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2003) 0.86
Colon carcinoma cells induce CXCL11-dependent migration of CXCR3-expressing cytotoxic T lymphocytes in organotypic culture. Cancer Immunol Immunother (2006) 0.86
Decision tree-based modeling of androgen pathway genes and prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2011) 0.86
Influence of Diabetes on the Interpretation of PET Scans in Patients With Esophageal Cancer. Gastrointest Cancer Res (2009) 0.85
Knowledge, attitudes, and self-efficacy as predictors of preparedness for oncology clinical trials: a mediational model. Med Decis Making (2013) 0.85
Sequelae of axillary lymph node dissection in older women with stage 1 and 2 breast carcinoma. Cancer (2002) 0.85
Effects of a decision support intervention on decisional conflict associated with microsatellite instability testing. Cancer Epidemiol Biomarkers Prev (2011) 0.85
Barriers to participation in cancer prevention clinical trials. Acta Oncol (2010) 0.84
Development of new agents for the treatment of advanced colorectal cancer. Clin Colorectal Cancer (2003) 0.84
Decisional conflict among patients who accept or decline participation in phase I oncology studies. J Empir Res Hum Res Ethics (2008) 0.84
Can molecular imaging predict response to preoperative chemoradiation in patients with rectal cancer? A Fox Chase Cancer Center prospective experience. Semin Oncol (2005) 0.83
The impact of misclassification due to survey response fatigue on estimation and identifiability of treatment effects. Stat Med (2011) 0.83